EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Chimeric antigen receptor‐based immunotherapy in breast cancer: Recent progress in China

Tianze Yu, Yuexin Lu, Jianwen Fang, Xiaocong Jiang, Yue Lu, Jingyan Zheng, Xi Shang, Haixing Shen, Peifen Fu

Cancer · 2024

DOI: 10.1002/cncr.35096 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, 2024. Verfasst von Tianze Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Breast Neoplasms, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Project of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is the fourth most prevalent cancer in China. Despite conventional treatment strategies, BC patients often have poor therapeutic outcomes, leading to significant global cancer mortality rates. Chimeric antigen receptor (CAR)‐based immunotherapy is a promising and innovative approach for cancer treatment that redirects immune cells to attack tumor cells expressing selected tumor antigens (TAs). T cells, natural killer (NK) cells, and macrophages, key components of the immune system, are used in CAR‐based immunotherapies. Although remarkable progress has been made with CAR‐T cells in hematologic malignancies, the application of CAR‐based immunotherapy to BC has lagged. This is partly due to obstacles such as tumor heterogeneity, which is further associated with the TA and BC subtypes, and the immunosuppressive tumor microenvironment (TME). Several combinatorial approaches, including the use of immune checkpoint inhibitors, oncolytic viruses, and antitumor drugs, have been proposed to overcome these obstacles in BC treatment. Furthermore, several CAR‐based immunotherapies for BC have been translated into clinical trials. This review provides an overview of the recent progress in CAR‐based immunotherapy for BC treatment, including targeting of TAs, consideration of BC subtypes, assessment of the TME, and exploration of combinatorial therapies. The authors focused on preclinical studies and clinical trials of CAR‐T cells, CAR‐NK cells, and CAR‐macrophages especially conducted in China, followed by an internal comparison and discussion of current limits. In conclusion, this review elucidates China’s contribution to CAR‐based immunotherapies for BC and provides inspiration for further research. Plain Language Summary Despite conventional treatment strategies, breast cancer (BC) patients in China often have poor therapeutic outcomes. Chimeric antigen receptor (CAR)‐based immunotherapy, a promising approach, can redirect immune cells to kill tumor cells expressing selected tumor antigens (TAs). However, obstacles such as TA selection, BC subtypes, and immunosuppressive tumor microenvironment still exist. Therefore, various combinatorial approaches have been proposed. This article elucidates several Chinese CAR‐based preclinical and clinical studies in BC treatment with comparisons of foreign research, and CAR‐immune cells are analyzed, providing inspiration for further research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenBreast NeoplasmsNeoplasmsHumansFemaleImmunotherapy, AdoptiveImmunotherapyAntigens, NeoplasmTumor Microenvironment

Stichwörter der Autor:innen

T cellsbreast cancerchimeric antigen receptorimmunotherapymacrophagesnatural killer cells

Substanzen

Receptors, Chimeric AntigenAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • School of Medicine, Zhejiang University, Hangzhou, China.
  • Department of Breast and Thyroid Surgery, First Affiliated Hospital of Huzhou University, Huzhou, China.
  • Department of Breast and Thyroid Surgery, Lishui People's Hospital, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
  • Department of Breast and Thyroid Surgery, Taizhou Hospital, Zhejiang University, Taizhou, China.
  • Department of Breast and Thyroid Surgery, Cixi People's Hospital, Cixi, China.

Förderung

  • Science and Technology Project of Zhejiang Province

Zitieren

APA

Yu, T., Lu, Y., Fang, J., Jiang, X., Lu, Y., Zheng, J., Shang, X., Shen, H., & Fu, P. (2024). Chimeric antigen receptor‐based immunotherapy in breast cancer: Recent progress in China. Cancer. https://doi.org/10.1002/cncr.35096

Vancouver

Yu T, Lu Y, Fang J, Jiang X, Lu Y, Zheng J, et al. Chimeric antigen receptor‐based immunotherapy in breast cancer: Recent progress in China. Cancer. 2024. doi:10.1002/cncr.35096

BibTeX
@article{Yu2024,
  author = {Yu, Tianze and Lu, Yuexin and Fang, Jianwen and Jiang, Xiaocong and Lu, Yue and Zheng, Jingyan and Shang, Xi and Shen, Haixing and Fu, Peifen},
  title = {Chimeric antigen receptor‐based immunotherapy in breast cancer: Recent progress in China},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35096}
}
Kostenlos starten →